ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
01/29/2025
Back to search
Official data from USPTO
VIRACTA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
01/30/2025
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
06/14/2022
Registration date
04/09/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/09/2024
Last transaction
01/30/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2023-10-00
First use in commerce
2023-10-00
Drawing code
5
Owner type
03
Owner location
Cardiff, CA
Examiner
ONUOHA, UKACHUKWU
Law office
O20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized word "VIRACTA" with all the elements in teal except for the dot above the "I" which is green.
Holders and representatives
Holders
Viracta Therapeutics, Inc.
Representatives
Alyssa M. Worsham WILSON SONSINI GOODRICH & ROSATI
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and therapeutic preparations for the treatment of patients with viral-associated cancers and other viral associated diseases and disorders; pharmaceutical productspharmaceutical products for treating cancer; pharmaceutical products for treating viral infections; pharmaceutical products for immune reconstitution; pharmaceutical products for cell-based immunotherapy; pharmaceutical products for T-cell adoptive transfer; pharmaceutical products for cellular adoptive transfer; pharmaceutical preparations for the treatment of cancertumorshematological malignancies; all of the foregoing containing antivirals
Class 42
Development of pharmaceutical preparations and medicines; drug discovery services; pharmaceutical drug development services; research relating to medicines in the nature of pharmaceutical research; medical research; pharmaceutical research and development services; medical research services in the field of cancerviral-associated cancers and other viral associated diseases and disorders; research and development of biological and chemical preparations for the treatment of cancerviral-associated cancers and other viral associated diseases and disorders; research and development of pharmaceutical productspreparations and compounds for the treatment of viral-associated cancers and other viral associated diseases and disorders; DNA screening and analysis services for scientific research purposes; research and development of pharmaceutical productspreparations and compounds for T-cell adoptive transferimmune reconstitutioncell-based immunotherapy; research and development of pharmaceutical productspreparations and compounds for the treatment of cancertumorshematological malignancies
Class 44
Providing medical informationconsultancy and advisory services; providing a website via a global computer network featuring medical information in the fields of cancerviral-associated cancers and other viral associated diseases and disorders
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/09/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/09/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/06/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/05/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/05/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/05/2024
IUAF
USE AMENDMENT FILED
01/16/2024
EISU
TEAS STATEMENT OF USE RECEIVED
01/16/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/25/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/30/2023
PUBO
PUBLISHED FOR OPPOSITION
05/30/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/26/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/21/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/21/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/21/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/03/2023
GNRT
NON-FINAL ACTION E-MAILED
04/03/2023
CNRT
NON-FINAL ACTION WRITTEN
04/03/2023
DOCK
ASSIGNED TO EXAMINER
03/27/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/27/2022
NWAP
NEW APPLICATION ENTERED
06/17/2022
Continuous trademark protection
Get notified about every new filing that threatens VIRACTA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.